BR9714632A - Pharmaceutical combination preparation, process for the production of pharmaceutical combination preparations, use of erythropoietin and iron preparations, and pharmaceutical packaging unit - Google Patents

Pharmaceutical combination preparation, process for the production of pharmaceutical combination preparations, use of erythropoietin and iron preparations, and pharmaceutical packaging unit

Info

Publication number
BR9714632A
BR9714632A BR9714632-3A BR9714632A BR9714632A BR 9714632 A BR9714632 A BR 9714632A BR 9714632 A BR9714632 A BR 9714632A BR 9714632 A BR9714632 A BR 9714632A
Authority
BR
Brazil
Prior art keywords
pharmaceutical
preparations
pharmaceutical combination
preparation
erythropoietin
Prior art date
Application number
BR9714632-3A
Other languages
Portuguese (pt)
Inventor
Paul Lelhann
Original Assignee
Roche Diagnolstics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnolstics Gmbh filed Critical Roche Diagnolstics Gmbh
Publication of BR9714632A publication Critical patent/BR9714632A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Clamps And Clips (AREA)

Abstract

<MU><B>PREPARADO DE COMBINAçãO FARMACêUTICA, PROCESSO PARA A PRODUçãO DE PREPARADOS DE COMBINAçõES FARMACêUTICAS, UTILIZAçãO DE PREPARADOS DE ERITROPOIETINA, E DE FERRO, E UNIDADE DE ACONDICIONAMENTO FARMACêUTICA<MV><D> A presente invenção relaciona-se com um preparado de combinação farmacêutica que compreende 250 - 20.000 U de um preparado EPO em formas de administração individuais e 5 - 20 mg de um complexo de Fe (III), em que o preparado EPO e o complexo de Fe (III) podem estar presentes em formas de administração separadas ou em uma forma de administração uniforme. O preparado farmacêutico é utilizado para tratar anemias ou pacientes de hemodiálise.<MU> <B> PHARMACEUTICAL COMBINATION PREPARATION, PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL COMBINATION PREPARATIONS, USE OF ERYTHROPOIETIN AND IRON PREPARATIONS AND PHARMACEUTICAL PACKAGING UNIT a <MV> related to this invention <MV> <D> pharmaceutical combination preparation comprising 250 - 20,000 U of an EPO preparation in individual administration forms and 5 - 20 mg of an Fe (III) complex, where the EPO preparation and the Fe (III) complex can be present in separate forms of administration or in a uniform form of administration. The pharmaceutical preparation is used to treat anemia or hemodialysis patients.

BR9714632-3A 1997-03-18 1997-03-18 Pharmaceutical combination preparation, process for the production of pharmaceutical combination preparations, use of erythropoietin and iron preparations, and pharmaceutical packaging unit BR9714632A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/001343 WO1998041226A1 (en) 1997-03-18 1997-03-18 Pharmaceutical combined preparations containing erythropoietin and iron preparations

Publications (1)

Publication Number Publication Date
BR9714632A true BR9714632A (en) 2000-05-23

Family

ID=8166555

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714632-3A BR9714632A (en) 1997-03-18 1997-03-18 Pharmaceutical combination preparation, process for the production of pharmaceutical combination preparations, use of erythropoietin and iron preparations, and pharmaceutical packaging unit

Country Status (19)

Country Link
US (1) US6710028B2 (en)
EP (1) EP0977582B1 (en)
JP (1) JP2000514092A (en)
AT (1) ATE222118T1 (en)
AU (1) AU726801B2 (en)
BR (1) BR9714632A (en)
CA (1) CA2284910C (en)
CZ (1) CZ296960B6 (en)
DE (1) DE59707988D1 (en)
DK (1) DK0977582T3 (en)
ES (1) ES2180958T3 (en)
HU (1) HU226204B1 (en)
IL (2) IL131959A0 (en)
NO (1) NO324661B1 (en)
NZ (1) NZ337465A (en)
PL (1) PL187479B1 (en)
PT (1) PT977582E (en)
SI (1) SI0977582T1 (en)
WO (1) WO1998041226A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
WO2005000340A1 (en) * 2003-06-27 2005-01-06 Pomytkin Igor A Synergistic compositions comprising erythropoietin and succinic acid (salt)
EP1696947B1 (en) * 2003-12-19 2014-02-26 F.Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
EP2067752A1 (en) * 2007-12-06 2009-06-10 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Construction material
US8536106B2 (en) 2010-04-14 2013-09-17 Ecolab Usa Inc. Ferric hydroxycarboxylate as a builder
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
NO881507D0 (en) * 1987-04-10 1988-04-07 Ortho Pharma Corp PROCEDURE FOR INCREASING THE HEMATOCRIT LEVEL FOR A NORMAL MAMMAL.
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
DE19535571A1 (en) * 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Combined pharmaceutical preparations and their use for the treatment of hemodialysis patients
EP0885613A1 (en) * 1997-06-21 1998-12-23 Roche Diagnostics GmbH Use of modified hemoglobins for treatment of anemias and erythropoietin and modified hemoglobin containing combined preparations
DE19734293A1 (en) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Use of pharmaceutical combination preparations containing erythropoietin and iron preparations for the treatment of rheumatic diseases
US20020065214A1 (en) * 2000-11-29 2002-05-30 Adrian Iaina Method of treating congestive heart failure
AU2002233230B2 (en) * 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates

Also Published As

Publication number Publication date
JP2000514092A (en) 2000-10-24
IL131959A0 (en) 2001-03-19
PL187479B1 (en) 2004-07-30
NZ337465A (en) 2002-04-26
ATE222118T1 (en) 2002-08-15
US20020094948A1 (en) 2002-07-18
NO994511D0 (en) 1999-09-17
NO324661B1 (en) 2007-11-26
AU2157297A (en) 1998-10-12
CZ296960B6 (en) 2006-08-16
WO1998041226A9 (en) 1999-11-25
EP0977582A1 (en) 2000-02-09
HU226204B1 (en) 2008-06-30
CA2284910C (en) 2003-01-28
AU726801B2 (en) 2000-11-23
US6710028B2 (en) 2004-03-23
PL335858A1 (en) 2000-05-22
PT977582E (en) 2002-12-31
EP0977582B1 (en) 2002-08-14
NO994511L (en) 1999-09-17
WO1998041226A1 (en) 1998-09-24
DK0977582T3 (en) 2002-12-16
HUP0001409A3 (en) 2003-08-28
DE59707988D1 (en) 2002-09-19
HUP0001409A2 (en) 2001-03-28
ES2180958T3 (en) 2003-02-16
IL131959A (en) 2006-12-31
CZ9903300A3 (en) 2001-03-14
SI0977582T1 (en) 2002-12-31
CA2284910A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
BR9714632A (en) Pharmaceutical combination preparation, process for the production of pharmaceutical combination preparations, use of erythropoietin and iron preparations, and pharmaceutical packaging unit
DK1289517T3 (en) Pharmaceutical compositions containing cannabidiol derivatives
ES2139678T3 (en) USE OF ERYTHROPOYETIN FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR PULMONARY ADMINISTRATION OR INHALATION.
EP0214647A3 (en) Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes
HUP0104709A2 (en) Use of erythropoietin or erythropoietin derivatives for the manufacture of a medicament for treatment of cerebral ischaemia
BR0014441A (en) Compositions that have improved stability
BR9609971A (en) Preparation of pharmaceutical combinations containing erythropoietin and iron preparations
TNSN97139A1 (en) DERIVATIVES OF ARYLSULFONYLAMINOHYDROXAMIC ACIDS
DE59309043D1 (en) Process for the production of pseudolatices and micro- or nanoparticles and pharmaceutical preparations containing them
TNSN00231A1 (en) CRYSTALLINE FORM OF 4-CARBOXYAMINO-2-SUBSTITUE-1,2,3,4- TETRAHYDROQUINOLEINE, AND COMPOSITIONS CONTAINING IT
WO2000074662A3 (en) Arthritis treatment
IL94267A0 (en) Compositions for treating skin disorders containing ketoconazole and their preparation
HU911928D0 (en) Process for the production of chelates and its complexes containing orto ligating functional group, and the medical preparations containing thereof
PT870761E (en) TIOCOLCHYCIN DERIVATIVES WITH ANTI-INFLAMMATORY AND MUSCULAR RELAXANT ACTIVITIES
ZA961395B (en) Metal complexes suitable for use in diagnosis and therapy
WO2001085165A3 (en) Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
BR0205944A (en) Ascorbic Acid Compounds, Synthesis Methods and Their Applications
IL118218A0 (en) Terpenoidic derivatives and pharmaceutical compositions containing them
KR960013376A (en) Anemia treatment containing iron and difructose
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
WO1999011256A8 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
TR200003451T2 (en) Pyrimidine-Aminomethyl-Pyridine Derivatives, Their Preparation and Their Use in the Control of Helicobacter Bacteria
DE68921051T2 (en) Pyridine-3-percarboxylic acid monopersulfate.
DE69941019D1 (en) Use of Amtolmetin Guacyl for the manufacture of a medicament for the prevention of platelet aggregation
ES2127133A1 (en) Use of 2,5-dihydroxybenzenesulphonic derivatives for the manufacture of drugs intended for the treatment and prevention of Alzheimer&#39;s disease

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO UMA VEZ QUE: - INCIDE NO ARTIGO 229 DA LEI 9279/96 SEGUNDO REDACAO DADA PELO ARTIGO 229-A DA LEI 10196/01; - NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM ART. 13 DA LPI); - NAO E CONSIDERADO INVENCAO, UMA VEZ QUE INCIDE NO ART. 10 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]